Catégorie : Ressources Documentaires

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, janvier 2022

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, janvier 2022. (5e version, janvier 2022....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 28 7 - Cannabinoïdes et Sommeil : 29 - 30 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57 11 - Cannabinoides et syndrome de Gilles [...]

Lire la suite

Early Consumption of Cannabinoids : From Adult Neurogenesis to Behavior, Citlalli Netzahualcoyotzi et al., 2021

Early Consumption of Cannabinoids : From Adult Neurogenesis to Behavior Citlalli Netzahualcoyotzi, Luis Miguel Rodríguez-Serrano, María Elena Chávez-Hernández and Mario Humberto Buenrostro-Jáuregui International Journal of Molecular Sciences, 2021, 22, 7450. doi : 10.3390/ijms22147450   Abstract The endocannabinoid system (ECS) is a crucial modulatory system in which interest has been increasing, particularly regarding the regulation of behavior and neuroplasticity. The adolescent–young adulthood phase of development comprises a critical period in the maturation of the nervous system and the ECS. Neurogenesis occurs in discrete regions of the adult brain, and this process is linked to the modulation of some behaviors. Since marijuana (cannabis) is the most consumed illegal [...]

Lire la suite

Cannabinoid Addiction: Behavioral Models and Neural Correlates, Rafael Maldonado et al., 2002

Cannabinoid Addiction: Behavioral Models and Neural Correlates Rafael Maldonado and Fernando Rodriguez de Fonseca The Journal of Neuroscience, 2002, 22, (9), 3326–3331. Abstract The use of cannabis sativa preparations as recreational drugs can be traced back to the earliest civilizations. However, animal models of cannabinoid addiction allowing the exploration of neural correlates of cannabinoid abuse have been developed only recently. We review these models and the role of the CB1 cannabinoid receptor, the main target of natural cannabinoids, and its interaction with opioid and dopamine transmission in reward circuits. Extensive reviews on the molecular basis of cannabinoid action are available elsewhere (Piomelli et al., [...]

Lire la suite

”State of the art on psychedelic research”, Iker Puente, 2018

”State of the art on psychedelic research" Iker Puente, PhD Integral European Conference (IEC) Siófok, Hungary, 27 May 2018   Psychedelic psychotherapy and research: history — 1st Phase: 1947-1970. First studies and beginning of research. — 2nd Phase: 1971-1989. Prohibition of studies and other uses. — 3nd Phase: 1990-2005. Beginning of new studies and research. — 4rd Phase: 2006-2016. Positive outcomes, change of social perception, blossoming of research, publications and positive media coverage. — Today: many studies in some of the most prestigious universities of the world: Johns Hopkins, Harvard, NYU, UCLA, Imperial College London… using MDMA, psilocybin, ketamine, LSD… (...)

Lire la suite

Cannabinoid modulation of drug reward and the implications of marijuana legalization, Dan P. Covey et al., 2015

Cannabinoid modulation of drug reward and the implications of marijuana legalization Dan P. Covey, Jennifer M. Wenzel, and Joseph F. Cheer Brain Research, 2015  1628, 233–243. doi : 10.1016/j.brainres.2014.11.034.   Abstract Marijuana is the most popular illegal drug worldwide. Recent trends indicate that this may soon change; not due to decreased marijuana use, but to an amendment in marijuana’s illegal status. The cannabinoid type 1 (CB1) receptor mediates marijuana’s psychoactive and reinforcing properties. CB1 receptors are also part of the brain endocannabinoid (eCB) system and support numerous forms of learning and memory, including the conditioned reinforcing properties of cues predicting reward or punishment. This is accomplished [...]

Lire la suite

On the Archetypal Nature of Bad Trips and Freakouts, Danny Wedding, Peter H Addy, 2014

On the Archetypal Nature of Bad Trips and Freakouts A Review of : "Confrontation With the Unconscious: Jungian Depth Psychology and Psychedelic Experience" by Scott J. Hill Danny Wedding, Peter H Addy PsycCRITIQUES, June 16, 2014, Vol. 59, No. 24, Article 4 © 2014 American Psychological Association   In 1967 Scott J. Hill had a terrifying and traumatic experience after taking LSD, experiencing “the depths of madness and hell” (p. xiii). He became suicidal and dissociated, and he wondered whether he had gone insane. Over the next four decades, he struggled with the terror he felt during that experience; he could not come to terms with [...]

Lire la suite

Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions, Rainer Spanagel, 2020

Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions Rainer Spanagel, PhD Dialogues in Clinical Neuroscience, 2020, 22, (3), 241-250. doi : 10.31887/DCNS.2020.22.3/rspanagel   The last decades have seen a major gain in understanding the action of cannabinoids and the endocannabinoid system in reward processing and the development of addictive behavior. Cannabis-derived psychoactive compounds such as Δ9-tetrahydrocannabinol and synthetic cannabinoids directly interact with the reward system and thereby have addictive properties. Cannabinoids induce their reinforcing properties by an increase in tonic dopamine levels through a cannabinoid type 1 (CB1) receptor–dependent mechanism within the ventral tegmental area. Cues that are conditioned [...]

Lire la suite

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders : Molecular Mechanisms and Targets, Rosa Maria Vitale et al., 2021

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets Rosa Maria Vitale, Fabio Arturo Iannotti and Pietro Amodeo International journal of Molecular Sciences, 2021, 22, 4876, 1-20. Doi : 10.3390/ijms22094876   Abstract : Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety, schizophrenia, epilepsy and drug addiction due to the ability of its versatile scaffold to interact with diverse molecular targets that are not restricted to the endocannabinoid system. Albeit the molecular mechanisms responsible for the therapeutic effects of CBD have yet to be fully elucidated, many [...]

Lire la suite

Cannabidiol as a Treatment for Mood Disorders : A Systematic Review – Le cannabidiol comme traitement des troubles de l’humeur : une revue systématique, Jairo Vinicius Pinto et al., 2020,

Cannabidiol as a Treatment for Mood Disorders : A Systematic Review Le cannabidiol comme traitement des troubles de l’humeur : une revue systématique Jairo Vinicius Pinto, MD, Gayatri Saraf, MD, Christian Frysch, MD, Daniel Vigo, MD, DrPH, Kamyar Keramatian, MD, MSc, FRCPC, Trisha Chakrabarty, MD, Raymond W. Lam, MD, Marcia Kauer-Sant’Anna, MD, PhD, and Lakshmi N. Yatham, MBBS, FRCPC The Canadian Journal of Psychiatry /La Revue Canadienne de Psychiatrie, 2020, Vol. 65, (4), 213-227. Doi : 10.1177/0706743719895195   Abstract Objective : To review the current evidence for efficacy of cannabidiol in the treatment of mood disorders. Methods : We systematically searched PubMed, Embase, Web of Science, PsychInfo, Scielo, [...]

Lire la suite

Cannabidiol as a treatment for craving and relapse inindividuals with cocaine use disorder: a randomizedplacebo-controlled trial, Violaine Mongeau-Pérusse, et al., 2021

Cannabidiol as a treatment for craving and relapse inindividuals with cocaine use disorder: a randomized placebo-controlled trial Violaine Mongeau-Pérusse, Suzanne Brissette, Julie Bruneau, Patricia Conrod, Simon Dubreucq, Guillaume Gazil, EmmanuelStip & DidierJutras-Aswad Addiction, 2021, 116, (9), 1-12. Doi : 10.1111/add.15417   ABSTRACT Background and Aims : Cocaine use disorder (CUD) is a significant public health concern for which no efficacious phar-macologicalinterventionsare available. Cannabidiol (CBD) has attracted considerable interest as a promisingtreatmentforaddiction. This study tested CBD efficacy for reducing craving and preventing relapse in people with CUD.DesignSingle-site double-blind randomized controlled superiority trial comparing CBD with placebo. Setting and Participants : Centre Hospitalier de l’Université de Montréal, Canada. Seventy-eight [...]

Lire la suite